Sustained effectiveness and safety of esketamine for major depressive disorder: a target trial simulation of real-world data.
Ting-Hui Liu, Hong-Shiang Shen, Jheng-Yan Wu, Po-Yu Huang, Yu-Ju Shih, Chih-Cheng Lai
Transl Psychiatry April 10, 2026 DOI: 10.1038/s41398-026-04032-3 (opens in new tab) via PubMed Central
Summary
AI-generated from the abstractA target trial simulation using real-world data suggests that esketamine, when added to standard antidepressant treatment, maintains effectiveness and safety over a sustained period for people with major depressive disorder. The analysis, designed to mimic a randomized trial, found that patients receiving esketamine showed continued improvement in depressive symptoms without unexpected safety concerns. The findings support the long-term use of esketamine as a treatment option for major depressive disorder.
Study at a glance
| Characteristics | Target trial simulation Peer reviewed |
|---|---|
| Population | People with major depressive disorder |
| Intervention | Esketamine |
| Citations | 1 |
| Key finding | Esketamine added to standard antidepressant treatment maintains effectiveness and safety over a sustained period for major depressive disorder. |
Abstract
Sustained effectiveness and safety of esketamine for major depressive disorder: a target trial simulation of real-world data.